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Abstract
Background: Hepatitis C virus (HCV) infects 170 million persons worldwide and is a public health problem.
Considering that HCV is principally transmitted by exposure to infected blood, multi-transfused patients constitute
one of the most important risk groups in developing countries. To explore the dynamics of this infection in
Colombia, we performed a study to determine the genotypes of HCV in a cohort of multi-transfused patients.
Results: The serum samples from patients positive for anti-HCV were evaluated for HCV RNA by nested-PCR of the
5’untranslated region (5’UTR). Viral genotype was determined by RFLP and/or automated sequencing. HCV subtype
1b was found in eight cases (66.7%) and subtype 1a in two cases (16.7%); seven isolates of subtype 1b were
obtained from patients who had received the first transfusion before 1986. Either genotypes 2b (8.3%) or 3a (8.3%)
were found in the remaining positive specimens.
Conclusions: This is the first HCV genotyping study developed in multi-transfused patients in Colombia where HCV
subtype 1b was the most prevalent. The mutation G235A in the 5’UTR of three isolates generated an additional
restriction site and an RFLP pattern different from those previously described for genotype 1.
Background
HCV infection is a global public health problem world-
wide. The virus persists in 60 to 85% of infected persons
and can lead to end-stage liver diseases and death. Indeed
HCV is a principal cause of cirrhosis and liver cancer and
a major indication for liver transplantation [1,2].
HCV is a single-stranded RNA virus classified into
the family Flaviviridae, genus Hepacivirus [3]. Six
major genetic groups and numerous subtypes have
been described with different geographical distribu-
tions, transmission routes and response to antiviral
treatments [2,4-7]. Subtypes 1a, 1b, 2b and 3a are
the most prevalent [8,9]; subtype 1b is predominantly
identified among individuals with history of blood transfu-
sions ; subtypes 1a and 3a are becoming more prevalent in
former intravenous drug users (IDU) [10-13].
In developed countries, voluntary blood donation,
blood donor education, history-based donor selection
and universal blood donor laboratory screening have
resulted in improved blood safety and reduced residual
risk for transfusion-transmissible infections (TTI), in-
cluding HCV [14,15]. However, TTI are still a public
health problem in developing countries [16].
A cross-sectional study carried out in Colombia showed
that the overall prevalence of HCV infection among 500
multi-transfused Colombian patients was 9%; the main
risk factors were being a patient with hemophilia, receiv-
ing transfusions before 1995 and having received ≥ 48
units of blood components [17].
To better understand the epidemiology of HCV in
Colombia, we characterized the HCV genotypes and
subtypes in this cohort of multi-transfused patients.
Results and discussion
The study population included 45 patients with HCV
antibodies from the cohort of the cross-sectional study
of multi-transfused patients (33 males, 12 females,
median age 50 years, median age of first transfusion 14
years). This study was carried out in four hospitals in
the two largest cities in Colombia, Bogota and Medellin.
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The HCV genome was detected by 5’UTR nested RT-
PCR in 12 (26.6%) of the 45 samples obtained from anti-
HCV positive multi-transfused patients. The yield rate
could be due to viral clearance, low viral load and/or the
long period of sample storage. A similar percentage,
28.8%, of HCV genome detection in anti-HCV positive
samples was reported in other study [18]; moreover the
probability of unsuccessfully PCR amplification is asso-
ciated with viral loads <100 copies/ml [8].
Ten of the 12 patients (83.3%) received the first trans-
fusion before 1993, the date when testing for HCV in
blood transfusions become mandatory in Colombia [17].
Clearly, the risk of HCV infection diminished dramatically
in the cohort after 1995. Additionally, all the patients with
hemophilia had received cryoprecipitate and 3 of them
had also received whole blood (Table 1); indeed the trans-
fusion of whole blood was identified as a risk factor in the
multivariate analysis of the cohort [17].
These results are consistent with the risk of receiv-
ing an HCV positive blood component in Colombia
estimated by 1994 (25.4 / 10.000 donations) and the
HCV screening coverage in blood donors reported in
the same period (67%). However, the screening cover-
age in 1997 was 100% and consequently this risk
decreased to 0 / 10.000 donations that year. This data
demonstrates the value of direct and indirect strat-
egies to improve transfusion policy [16,19]
To analyze the distribution of the different HCV
genotypes in this population, we first performed an
analysis by RFLP. A comparison among RFLP restriction
patterns obtained and those generated by bioinformatics
with GenBank sequences allowed the identification of five
isolates as subtype 1b, two as subtype 1a, one as genotype
2 and one as genotype 3. In some samples, the viral sub-
type could not be established by this method due to the
similarity between patterns. Unexpectedly, three isolates
(HCVCOL_172, 478, XX1) showed a restriction pattern
similar to that of genotype 6 (Figure 1).
To verify the results obtained by RFLP, the PCR pro-
ducts of eight isolates (HCVCOL_175, 224, 120, 278,
XX6, 172, 478 and XX1) were directly sequenced using
primers 940 and 211. Analysis of these sequences by
BLAST made it possible to confirm the subtypes 1a and
1b, and to determine the subtypes 2b and 3a. Moreover,
the three isolates with the unexpected RFLP pattern
(HCVCOL_172, 478 and XX1) were identified as geno-
type 1 with a similarity of 98%.
The phylogenetic tree using the neighbor-joining method
showed the expected clades for the HCV prototypes
(Figure 2). Isolates HCVCOL_175, 224, 120, 278 and
XX6 were grouped into the same genotypes/subtypes
previously designated by RFLP and BLAST. On the
other hand, the isolates HCVCOL_172, 478 and XX1
were grouped in genotype 1 based on phylogenetic
analysis. These results suggest a limitation of the 5’UTR
RFLP-based genotyping method to discriminate the
pattern of some strains of genotype 1. The inferring
consensus tree showed a similar topology; indeed, the
clade of genotype 1 was supported by high bootstrap
values. This finding was confirmed by maximum par-
simony analyses (data not shown).
To assess the differences observed between the techni-
ques used to identify the HCV genotypes, the sequences
of the strains HCVCOL_172, 478, XX1 were aligned
with HCV sequences previously reported in patients
from Argentina and Uruguay (Figure 3). The Colombian
isolates with the unexpected RFLP pattern were grouped
into one sub-clade together with isolates of genotype 1,
subtype 1b from Argentina and Uruguay [20]. Based on
the HCV genome sequence described by Choo et al. [3],
two unique substitutions were found; these mutations
were localized at nucleotides −96 and −235. The former
substitution corresponds to the change from adenine to
guanine (A96G) and the second one to the transition
G235A. When the substitutions were compared with the
sequences recognized by each restriction enzyme used in
the RFLP assay, a polymorphism (GTGC to GTAC) was
detected that correlates with the substitution G235A
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Figure 1 (See legend on next page.)
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generating a restriction site for the enzyme RsaI (GTGC
to GTAC), modifying the RFLP pattern of genotype 1.
This polymorphism had been previously described in
samples obtained from patients with chronic HCV infec-
tion in Argentina and Uruguay [21].
On the other hand, relevant substitutions were observed
at positions −96 and −135 positions (G96A, C135A)
in some strains, as well as an insertion of adenine at
nucleotide −66 (66A) in one isolate (data not shown).
All these mutations were located in domain III of
the Internal Ribosome Entry Site (IRES), a secondary
structure of the viral genome that mediates recogni-
tion by the 40S ribosomal subunit and the binding of
the translation initiation factor 3 (eIF3). Further stud-
ies are necessary to determine the biological conse-
quences of these mutations [22-24].
Based on the results of the phylogenetic analysis and/
or RFLP, the circulation of HCV genotype 1, subtypes 1b
(8/12, 66.7%) and 1a (2/12, 16.6%), genotype 2, subtype
2b (1/12, 8.3%) and genotype 3, subtype 3a (1/12, 8.3%)
was confirmed in this high risk population (Table 1).
A number of studies were carried out previously to de-
scribe the HCV distribution in donors and patients with
chronic liver diseases in Colombia [18,25-28]. Subtype
1b was the most frequently found in all these studies, al-
though only two such studies correspond to phylogenetic
analyses of HCV samples. In the first study, Mora et al.
[18] explored the HCV genotype distribution among 53
samples from blood donors. As described in other South
American countries, subtype 1b was the most prevalent in
this donors population (82.8%); interestingly, this preva-
lence is one of the highest described among different stud-
ies performed worldwide. The distribution of the other
subtypes and genotypes in this population donor was 1a
5.7%, 2a 5.7%, 2b 2.8%, and 3a 2.8%. The second study
corresponds to the description of HCV genotypes in sam-
ples of liver tissue obtained from patients with end-stage
liver diseases. The strains were grouped into subtypes 1a
(one sample) and 1b (three samples) [29].
As mentioned above, HCV subtype 1b is mostly found
among persons with a history of blood transfusion and
among older individuals. Moreover, several studies have
linked HCV subtype 1b to patients with bleeding disorders
[30,31]. In the present study genotype 1 was the only
genotype characterized in patients with hemophilia: five
patients were infected with subtype 1b and two patients
had subtype 1a (Table 1). The five patients in other
diagnostic categories (hemodialysis, acute bleeding or
oncologic illnesses) were infected with three different
genotypes/subtypes, 1b (3 patients), 2b (1 patient) and
3a (1 patient) suggesting a more diverse origin of their
infections.
Furthermore, seven isolates of subtype 1b characterized
in our study were obtained from patients who had
received their first transfusion before 1986. HCV screening
of blood donors became mandatory in Colombia in 1993;
but its universal coverage was not reached until 1997 [32].
In fact, Mora et al. [18] estimated that HCV subtype1b
was introduced in Bogota around 1950 and spread expo-
nentially in the period 1970 to 1990 probably carried out
by blood transfusion. As described by Romano et al. [33]
in Brazil, subtype 1b was the first HCV subtype intro-
duced in Sao Paulo that possibly spread by blood trans-
fusion and unsafe medical practices. Subtype 1b was
followed by subtype 3a, and finally subtype 1a was the
last subtype to emerge.
Subtypes 1a and 3a have been related to IDU in some
studies [10-13]. However the predominance of subtype
1a found among hemodialysis patients in Brazil and the
risk of infection related with the length of the time on
hemodialysis suggested nosocomial HCV transmission
[34]. In the present study subtype 1a was found in two
samples from patients with hemophilia, whereas subtype
3a was detected in one hemodialysis patient.
This dynamics of HCV was recently also demonstrated
in a cohort of repeat donors in the USA in the period
January 2006 through December 2009. Subtype 1a was
the most frequent HCV genotype in prevalent and incident
cases; subtype 3a strains were significantly more frequent in
incident cases whereas subtype 1b was less frequent in inci-
dent than in prevalent cases [8]. These results suggest that
subtypes 1a and 3a have emerged recently and are spread-
ing rapidly in some countries [10-13].
Additional studies and analysis of others HCV genome
regions should be conducted in order to establish the
phylogenetic relationship among HCV sequences obtained
from Colombian blood donors, patients with chronic liver
disease and multi-transfused patients [35]. The analysis of
HCV sequences by genotype, clinical status, year of isola-
tion and geographic origin could provide evidence of the
HCV infection pattern spread in Colombia.
In conclusion, this is the first report on HCV genotypes
among multi-transfused patients in Colombia where sub-
type 1b was the most prevalent. The mutation G235A in
the 5´UTR of three HCV isolates generated an additional
restriction site and, therefore, an RFLP pattern different
from those previously described for genotype 1. Although
the number of samples analyzed is relatively small,
(See figure on previous page.)
Figure 1 Identification of patterns obtained by restriction endonuclease digestion of HCV 5'UTR sequences. WM: Molecular Weight
marker 10 bp ladder. A. Restriction patterns of samples generated by RFLP. B. In silico restriction patterns of Genbank sequences generated by
Bioedit software; Genbank accession numbers (EF407413, EU155330, AY232735, AF046866, EF424629). ES: Expected size of digested fragments.
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Figure 2 Phylogenetic analysis of 5'UTR sequences of HCV strains. Rooted phylogenetic tree generated with program PAUP and neighbor
joining method. The arrows correspond to samples from multi-transfused patients of this study. Shaded areas indicate the expected clusters of
sequences prototypes. The sequence of HCV genotype 5 was used as out-group (Y13184).
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the results of this study have interesting implications
regarding the HCV genotypes in a population exposed
to blood transfusion during the time when TTI repre-
sented a serious health problem in Colombia. Molecular
epidemiology studies are very important to under-
stand the transmission dynamics of HCV infection
in Colombia and in Latin America.
Methods
Study population
Five hundred multi-transfused patients were recruited at
the Pan American Health Organization (PAHO) multi-
center study between February and September 2003 in
four hospitals of the two largest cities in Colombia,
Bogota and Medellin. The present study was carried
out with samples from 45 anti-HCV positive patients
of this cohort.
The serum samples were stored at −70°C in air tight
vials with plug seal caps, since their collection in 2003,
and not thawed until immediately before the analysis.
Ethics statement
All procedures adopted in this study were followed the
terms established by the Ethics Committees of PAHO,
Universidad de Antioquia, Instituto Nacional de Salud
and Instituto Nacional de Cancerologia. The terms of
informed consent were signed by all patients.
Molecular detection of HCV
Total RNA was extracted from samples using TRIzol LS
Reagent (Invitrogen). The 5 HCV ´UTR was detected by
RT-nested PCR, as described by Chan et al. [36]. For
cDNA synthesis, the viral RNA was reverse transcribed
using primer 209 and Moloney Murine Leukemia Virus
reverse transcriptase (Invitrogen). The 5´UTR was amp-
lified by nested PCR using primers 209 and 939 and pri-
mers 940 and 211[36]. The amplified products were
analyzed by agarose gel electrophoresis.
RFLP analysis and sequencing for genotype identification
To determine the HCV genotype, RFLP analyses were
performed as described by Davidson et al. [37] with
Figure 3 Alignment of HCV 5´UTR sequences from Colombian multi-transfused patients. M62321: sequence genotype 1a USA; EF424629:
sequence genotype 6 Taiwan. Colombian multitransfused HCV Δ; Uruguay HCV ○ sequences; Argentina HCV ● sequences.
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some modifications. Briefly, the amplified products were
digested in separate reactions with the restriction enzymes
RsaI, HinfI or MvaI at 37°C for 1 hour, and thereafter with
BstUI at 60°C for 1 hour. Two cycles of enzyme denatur-
ation were then performed at 95°C for 10 min. The
digested products were analyzed by polyacrylamide gel
electrophoresis. The genotype was determined by the
pattern of each sample and compared with the pre-
dicted restriction patterns of 50 HCV sequences avail-
able in GenBank, using the BioEdit 7.9.0.0 software
(lbis Biosciences, Canada).
Phylogenetic analysis of the HCV 5´UTR
Phylogenetic analysis of the 5´UTR sequences was carried
out to identify the clade and subtype distribution. The
amplified 5´UTR fragment was purified and sequenced
(Macrogen, Korea) using the automated dideoxynucleotide
method (BigDyeTM terminator). A total of 106 prototype
HCV sequences available in GenBank were included in
the analysis. Rooted neighbor-joining and maximum
parsimony trees were constructed using the PAUP 4.0
(Phylogenetic Analysis Using Parsimony) and the Mega
4.1 (Molecular Evolutionary Genetics Analysis) software.
Reliability of the trees was evaluated statistically by boot-
strap analyses with 100 and 1000 replicates, respectively.
Pair-wise comparison of HCV isolates
HCV samples that exhibited no identifiable pattern by RFLP
were sequenced and subjected to pair-wise comparisons.
The sequence of each HCV sample was aligned with refer-
ence sequences using the BioEdit 7.9.0.0 software. Genbank
accession numbers of reference sequences: Argentina
isolates (DQ077819, AY376833, AY376834, AY376835,
AY376836, AY376837), Uruguay isolates (AJ012831,
AJ012832), and prototype sequences (M62321, EF424629,
HCVCOL_224) of the genotypes 1a, 1b and 6, respectively.
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